LLY

1,081.58

-1.94%↓

JNJ

224

-0.52%↓

ABBV

213.26

-2.16%↓

UNH

378.3

-0.09%↓

MRK

115.22

-2.85%↓

LLY

1,081.58

-1.94%↓

JNJ

224

-0.52%↓

ABBV

213.26

-2.16%↓

UNH

378.3

-0.09%↓

MRK

115.22

-2.85%↓

LLY

1,081.58

-1.94%↓

JNJ

224

-0.52%↓

ABBV

213.26

-2.16%↓

UNH

378.3

-0.09%↓

MRK

115.22

-2.85%↓

LLY

1,081.58

-1.94%↓

JNJ

224

-0.52%↓

ABBV

213.26

-2.16%↓

UNH

378.3

-0.09%↓

MRK

115.22

-2.85%↓

LLY

1,081.58

-1.94%↓

JNJ

224

-0.52%↓

ABBV

213.26

-2.16%↓

UNH

378.3

-0.09%↓

MRK

115.22

-2.85%↓

Home・Lista de Ações・Charles River Laboratories International Inc

Charles River Laboratories International Inc

Abrir

SetorSaúde

183.18 1.18

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

176.29

Máximo

184.26

Indicadores-chave
By Trading Economics
Rendimento	262M -15M
Vendas	1.6M 996M
EPS	-0.3
Margem de lucro	-1.486
Funcionários	18,300
EBITDA	-11M 187M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+15.32% upside

Dividendos
By Dow Jones
Próximos Ganhos	5 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-781M 7.7B
Abertura anterior	182
Fecho anterior	183.18

Sentimento de Notícias

By Acuity

50%

124 / 344 Ranking em Healthcare

Charles River Laboratories International Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

31 de mai. de 2026, 23:44 UTC

Conversa de Mercado

Nikkei May Remain Rangebound Amid Middle East Uncertainty -- Market Talk

31 de mai. de 2026, 23:36 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

31 de mai. de 2026, 23:36 UTC

Conversa de Mercado

Oil Rises Amid Few Signs of Strait of Hormuz's Reopening -- Market Talk

31 de mai. de 2026, 23:36 UTC

Conversa de Mercado

Watch for Data-Center Investment in Australia's 1Q GDP Print -- Market Talk

31 de mai. de 2026, 22:54 UTC

Aquisições, Fusões, Aquisições de Empresas

Berkshire Hathaway to Buy Homebuilder Taylor Morrison for $6.8 Billion -- WSJ

29 de mai. de 2026, 23:08 UTC

Aquisições, Fusões, Aquisições de Empresas

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29 de mai. de 2026, 23:06 UTC

Aquisições, Fusões, Aquisições de Empresas

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29 de mai. de 2026, 20:53 UTC

Ganhos

Oil Declines Lift Stocks to Fresh Records -- WSJ

29 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

29 de mai. de 2026, 20:33 UTC

Conversa de Mercado

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29 de mai. de 2026, 20:11 UTC

Ganhos

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 de mai. de 2026, 19:47 UTC

Ganhos

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29 de mai. de 2026, 19:36 UTC

Conversa de Mercado

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29 de mai. de 2026, 19:34 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

29 de mai. de 2026, 19:34 UTC

Conversa de Mercado

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29 de mai. de 2026, 19:22 UTC

Conversa de Mercado

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29 de mai. de 2026, 19:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29 de mai. de 2026, 18:19 UTC

Conversa de Mercado

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29 de mai. de 2026, 18:12 UTC

Aquisições, Fusões, Aquisições de Empresas

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29 de mai. de 2026, 18:11 UTC

Conversa de Mercado

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29 de mai. de 2026, 18:10 UTC

Conversa de Mercado

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29 de mai. de 2026, 17:55 UTC

Ganhos

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 de mai. de 2026, 17:55 UTC

Conversa de Mercado

NEAR Protocol Nearly Doubles in May -- Market Talk

29 de mai. de 2026, 17:38 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29 de mai. de 2026, 17:00 UTC

Ganhos

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

29 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

29 de mai. de 2026, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

29 de mai. de 2026, 16:02 UTC

Conversa de Mercado

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29 de mai. de 2026, 15:55 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

Comparação entre Pares

Variação de preço

Charles River Laboratories International Inc Previsão

Preço-alvo

By TipRanks

15.32% parte superior

Previsão para 12 meses

Média 208.4 USD 15.32%

Máximo 235 USD

Mínimo 160 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Charles River Laboratories International Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

11 ratings

Comprar

Manter

Vender

Com base em 11 analistas que deram avaliações de ações para Charles River Laboratories International Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

124 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.